Back to results
US 2008/0305049 A1Published application
Mri Contrast Agents for Diagnosis and Prognosis of Tumors
OwnerHadassa Degani, David Steininventors
Life of this patent
Estimating the term…
Abstract
The invention relates to bifunctional conjugates comprising a receptor ligand moiety and a metal binding moiety and complexes thereof with paramagnetic lanthanide or transition metals, and to the use of the metal complexes as contrast agents in magnetic resonance imaging (MRI) of tumors and other abnormalities.
Claims48
A conjugate of the general formula I, II or III:
- L is a moiety of a ligand of a receptor associated with malignant tumors or a chemotherapeutic drug moiety;
- X1 is a C2-C10 hydrocarbylene chain;
- X2 is phenylene or a covalent bond;
- R1 to R4 in the conjugates of formulas I and II and R1 to R3 in the conjugate of formula III, each is H, (C1-C4) alkyl or CH2R7;
- R5 and R6 each is H or (C1-C4) alkyl;
- R7 is selected from the group consisting of —COOR8, —COO−,
- —PO32− and —CONHR8;
- R8 and R9 each is selected from the group consisting of H, (C1-C4) alkyl, phenyl and benzyl, wherein the phenyl or benzyl can be substituted by at least one group selected from the group consisting of halogen, (C1-C4) alkyl and OR5;
- the dotted lines, when present, define that the N atom and the 2 adjacent C atoms are part of a mono- or polycyclic ring;
- and metalated complexes of a conjugate of formula I, II or III, wherein R1 to R4 each is —CH2R7 and R7 is —COOR8, —COO−, PO2(R8)(R9), PO32−, PO3H2 or —P(R9)O2− with a paramagnetic lanthanide metal selected from the group consisting of Gd (III), Eu(III), Dy(III), Tb(III), Tm(III), Yb(III) and Pr(III), and of a conjugate of formula I, II or III, wherein R, to R4 each is H, (C1-C4) alkyl or —CH2R7 and R7 is as defined above, with a paramagnetic transition metal selected from the group consisting of Mn(II), Co(III), Ni(III), Fe(II) and Fe(III).
7 more elements
48-52. (canceled)
Dependencies are inferred from the claim text.